Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2024-08-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '주식회사 큐리언트' covering the period from January 1, 2024, to June 30, 2024. It is a comprehensive regulatory filing submitted to the Financial Supervisory Service (FSS) and the Korea Exchange, containing detailed company information, business operations, and financial data. This fits the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by UAMCO Keystone and its special related parties in Curient Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership changes and the purpose of holding (influence on management).
2024-08-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the acquisition of shares by Dongkoo Bio & Pharma and its special related parties in Curient Co., Ltd. due to a third-party capital increase. This falls under the category of Major Shareholding Notification.
2024-08-05 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Qurient regarding the results of a third-party capital increase (issuance of new shares). It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-07-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and the addition of special related parties (joint holders) for the company 'Curient'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes in control.
2024-07-25 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (항암치료제 Q901 단독요법 및 병용요법에 대한 식품의약품안전처(MFDS) 임상 제1/2상 임상시험계획변경승인신청)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Curient) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding an application for an amendment to a clinical trial plan (IND amendment) for their cancer drug Q901. Since this is a specific regulatory disclosure of a material event (clinical trial status) rather than a general report, financial statement, or presentation, it falls under the 'Regulatory Filings' category.
2024-07-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.